Clearly very little traffic here jter1 !. 2 potential sources of...

Clearly very little traffic here jter1 !. 2 potential sources of news near term. 1) progress on trial (initially ethics approval then initiation) and 2) feedback from industry partners and roadmap to commercialise.

Fibrosis is huge but VBS is not really tooting it's own horn vs others in the market

Key is there is no current treatment for liver fibrosis where VBS compound VB0004 has proven ability to not only stop but reverse fibrosis. Also proven in heart and pulmonary meaning target market is huge and there will be a lot of interest in scientific / BP circles in outcome of P1 trial about to be underway. VBS aim is to prove efficacy and license at P1 stage see below;

Liver Fibrosis alone is building towards a $25b market with no known cure.


From Karen Duggan in recent presentation to the market





Similar results in heart and pulmonary fibrosis...


Phase 1 about to begin. Global pharma already engaged with aim to license at P1 stage

And the really interesting part

1) VBS aims to license VB0004 to international pharma based on results of P1 ie this could come in late 2021 and early data is likely to be made available to help publicise progress and drive up potential license price
2) VBS is also a 100% owner of Accugen a potential platform play for rapid genomic analysis. This is essentially stealth mode for now but feedback from partner institutions and initial commercialisation plans should come early 2021.

Only 32m SOI and very tight trading...

Hence potential for VBS to rerate from MC of $40m to $100m on initial P1 data and Accugen progress 1H 2021 and >$250m by end 2021 based on positive P1 data (licensing discussions) and Accugen progress.